Статья
ПРОБИОТИКИ В ЛЕЧЕНИИ И ПРОФИЛАКТИКЕ ИНФЕКЦИОННЫХ ОСЛОЖНЕНИЙ НЕЙРОГЕННОГО МОЧЕВОГО ПУЗЫРЯ
Нейрогенный мочевой пузырь (НМП) – это дисфункция в работе мочевого пузыря, обусловленная врожденной или приобретенной патологией нервной системы, которая является распространенным патологическим состоянием и проявляется невозможностью осуществления произвольно-рефлекторного накопления и выделения мочи из-за органического и функционального поражения нервных центров и путей, что в значительной мере осложняет качество жизни пациентов. Нейрогенный мочевой пузырь часто сопровождается миофасциальным синдромом, синдромом тазового венозного застоя и инфекционными осложнениями.Цель исследования. Оценить эффективность пробиотиков в профилактике симптоматической инфекции мочевого пузыря (ИМП) у больных с невропатией мочевого пузыря по данным, представленным в отечественной и зарубежной литературе.Методы исследования. Проведен поиск литературных инсточников с 1993 по 2023 гг в базах данных CENTRAL, MEDLINE и EMBASE, материалов конференций, поискового портала Международного регистра клинических испытаний (ICTRP) рандомизированных контролируемых исследований (РКИ), посвященных использованию пробиотиков для профилактики ИМП у пациентов с нейропатией мочевого пузыря.Результаты. Необходимым критериям РКИ соответствовали три исследования с участием 109 пациентов. В данных исследованиях изучалась эффективность введения пробиотиков в мочевой пузырь для создания безвредной колонии микроорганизмов в мочевыводящих путях у больных с дисфункцией мочевого пузыря.Выводы. Показана относительная безопасность введения пробиотиков в мочевой пузырь для создания безвредной колонии микроорганизмов в мочевыводящих путях у больных с дисфункцией мочевого пузыря. Эффективность использования пробиотиков с целью предупреждения развития инфекционных осложнений у больных с нейрогенным мочевым пузырем не доказана. Необходимы дальнейшие тщательно спланированные исследования.
1. Neurogenic Bladder: Epidemiology, Diagnosis, and Management. / J.N. Panicker// J. Semin Neurol. – 2020. – Vol.40, №5. ‒ P.569-579.
2. Neurogenic Bladder: Assessment and Operative Management. /M.E. DeWitt-Foy [et.al]// J. Urol Clin North Am. – 2022. Vol.49, №3. ‒ P.519-532.
3. Neurogenic Bladder Management. / J.K. Lee // J. Radiol Technol. ‒ 2021. – Vol.92, №3. ‒ P.281-295.
4. Time of onset and factors associated with delayed response post intradetrusor injection of onabotulinumtoxin a in patients with neurogenic and idiopathic overactive bladder syndrome. / T. Al-Shaiji [et al.] // J. Urol Ann. ‒ 2023. Vol.15, №2. ‒ P. 133-137.
5. Non-surgical urologic management of neurogenic bladder after spinal cord injury. /Romo PGB [et al.]// World J Urol. 2018. – Vol.36, №10.-P.1555-1568.
6. Pilot trial of bacterial interference for preventing urinary tract infection. / R.O. Darouiche [et.al.]// J. Urology. ‒ 2001. ‒ Vol.58, №3. ‒ P.339-44.
7. Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder / R.O. Darouiche [et. al.]// J. Urology. – 2011. Vol.78, №2. ‒ P.341- 6.
8. Rare emergence of symptoms during long term asymptomatic Escherichia coli 83972 carriage without an altered virulence factor repertoire/ B. Köves [et al.]// Journal of Urology. ‒ 2014. – Vol.191, №2. ‒ P.519-28.
9. Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying/F. Sunden [et al.]// Journal of Urology. – 2010. ‒ Vol.184, №1. ‒ P.179-85.
10. Bacterial interference is deliberate colonization with Escherichia coli 83972 an alternative treatment for patients with recurrent urinary tract infection? / F. Sundén // International Journal of Antimicrobial Agents. – 2006. – Vol.28, №1. ‒ P.26-29.
11. Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women/ C.A. Czaja [et.al.]// J. Infectious Diseases in Obstetrics & Gynecology. – 2007. Vol.3, №5. ‒ P.387.
12. Randomised trial of cranberry‐lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women / Kontiokari T. [et al.] // BMJ. ‒ 2001. – Vol.322, №7302. ‒ P.1571.
13. The effect of probiotic prophylaxis for preventing recurrent urinary tract infection in children with persistant primary vesicoureteral reflux [abstract no: COD. PP 81] / S.J. Lee [et al.]// J. Pediatric Nephrology. ‒ 2006. – Vol.21, №10. ‒ P.1542.
14. Probiotics prophylaxis in children with persistent primary vesicoureteral reflux/ S.J. Lee [et al.]// J. Pediatric Nephrology. ‒ 2007. – Vol.22, №9. ‒ P.1315‐20.
15. Combination of probiotics and antibiotics in the prevention of recurrent urinary tract infection in children / M.J. Mohseni [et al.]// Iranian Journal of Pediatrics. ‒ 2013. ‒ Vol.23, №4. ‒ P.430-8.
16. Predictive value of Escherichia coli susceptibility in strains causing asymptomatic bacteriuria for women with recurrent symptomatic urinary tract infections receiving prophylaxis / M.A. Beerepoot [et al.]// J. Geerlings SE. Clinical Microbiology & Infection. – 2012. ‒ Vol.18, №4. ‒ P. 84-90.
17. Research priorities for urological care following spinal cord injury: recommendations of an expert panel/ K.C. Hayes [et al.]// Canadian Journal of Urology. – 2007. ‒ Vol.14, №1. ‒ P.3416-23.
18. Lactobacillus rhamnosus gr-1 and l. Reuteri rc-14 versus trimethoprim/sulfamethoxazole (TMP/SMX) in the prevention of recurrent urinary tract infections (RUTIs) in postmenopausal women: a randomized double blind non-inferiority trial [abstract no: L1 1656a]/M.A. Beerepoot, W.M. Wal, S. Nys// 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). - 2009 Sep 12-15; San Francisco (CA). 2009. ‒ Р. 15-27.
19. Re: Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women/ E.M. Schaeffer// Journal of Urology. ‒ 2013. – Vol.189, №4.-P.1332-3.
20. Probiotics improvement of gastrointestinal and genitourinary health in girls with spina bifida (H-23245)/ E.A. Jones// BMJ. ‒ 2008. ‒ Р. 33-49.
21. H-23187: Probiotic prophylaxis against recurrent pediatric urinary tract infection/ D.R. Roth // JCT– 2008. – Р. 117-123.
22. Measuring inconsistency in meta-analyses/ J.P. Higgins [et al.]// BMJ. – 2003, Vol.327, №7414. ‒ P.557-60.
23. Influence of three-day antimicrobial therapy and lactobacillus vaginal suppositories on recurrence of urinary tract infections/ G. Reid [et al.]// J. Clinical Therapeutics. ‒ 1992. – Vol.14, №1. ‒ P.11-26.
24. Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a study protocol for a randomised controlled trial/ B. Lee [et al.]//BMC Urology. - 2016. – Vol.16.-P.18.
25. Prophylaxis of spinal cord injury urinary tract infection therapeutic trial (ProSCIUTTU): protocol [abstract]. 53rd ISCoS Annual Scientific Meeting; 2014 Sep 2-4; Maastricht, Netherlands / S.L. Toh [et al.]// ‒ 2014. ‒ Р. 1044-1050.
26. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review / R. Barrons, D. // J. Tassone Clinical Therapeutics. – 2008. ‒ Vol.30, №3. ‒ P.453-68.
27. Cardenas, D.D. Urinary tract infection in persons with spinal cord injury. / D.D. Cardenas, T.M. Hooton// J. Archives of Physical Medicine & Rehabilitation. ‒ 1995. ‒ Vol.76, № 3. ‒ P.272-80.
28. A study of non-antibiotic versus antibiotic prophylaxis for recurrent urinary-tract infections in women (the NAPRUTI study) [Onderzoek naar niet-antibiotische versus antibiotische profylaxe bij vrouwen met recidiverende urineweginfecties (de NAPRUTI-studie)] /M.A. Beerepoot, E.E. Stobberingh, S.E. Geerlings//J. Nederlands Tijdschrift voor Geneeskunde. ‒ 2006. ‒ Vol.150, №10. ‒ P.574-5.
29. Beerepoot, M.A. Recurrent urinary tract infections. Antibiotic resistance and non-antibiotic prophylaxis [abstract no:SP34-2]/ M.A. Beerepoot// International Journal of Antimicrobial Agents. – 2013. Vol.42, № 2. ‒ P.38.
30. Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial / R.O. Darouiche [et.al.]// J. Clinical Infectious Diseases. – 2005. ‒ Vol.41, №10. ‒ P.1531.
31. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies/ Falagas M.E. [et.al.]// J. Drugs. – 2006. ‒ Vol.66, №9. ‒ P.1253-61.
32. Probiotics: what are they? What are their effects on gut physiology? / J. Fioramonti [et.al.]// J. Best Practice & Research Clinical Gastroenterology. ‒ 2003. ‒ Vol.17, №5. ‒ P.711-24.
33. High prevalence of nosocomial infections in rehabilitation units accounted for by urinary tract infections in patients with spinal cord injury / R. Girard [et.al.]// Journal of Hospital Infection. – 2006. ‒ Vol.62, №4. ‒ P.473-9.
34. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations/ G.H. Guyatt [et. al.]// BMJ. – 2008. ‒ Vol.336, №7650. ‒ P.924-6.
35. Mark Haran, Madeleine King, Martin Stockler, Obad Marial, Bonne Lee, 2017. «Validity of the SF-36 Health Survey as an outcome measure for trials in people with spinal cord injury,»CHERE, University of Technology, Sydney. / M.J. Haran [et.al.]// ‒ Working Papers 2017/4. ‒ Р.1-8.
36. Health status rated with the medical outcomes study 36 item short form health survey after spinal cord injury/ M.J. Haran [et.al.]// J. Archives of Physical Medicine & Rehabilitation. – 2005. Vol.86, №12. ‒ P.2290-5.
37. Exclusion of uropathogen adhesion to polymer surfaces by Lactobacillus acidophilus/ L.A. Hawthorn [et al.]// Journal of Biomedical Materials Research. – 1990. Vol.24, №1. ‒ P.39‐46.
38. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
39. Urinary tract infection prophylaxis using Escherichia coli 83972 in spinal cord injured patients /R. Hull [et al.]// Journal of Urology. – 2000. Vol.163, №3. ‒P.872‐7.
40. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection/ Y. Kariyama [et al.]//International Journal of Antimicrobial Agents. – 2006. ‒ Vol.28, № 1. ‒ P.30-4.
41. Neurogenic bladder. In: Frontera WR, Silver JK, Rizzo TD editor(s)/ A.M. Kaynan [et al.]// J. Essentials of Physical Medicine and Rehabilitation: Musculoskeletal Disorders, Pain and Rehabilitation. 2nd Edition. Philadelphia: Saunders Elsevier. ‒ 2008.
42. Paediatrics Manual: The Children's Hospital at Westmead Handbook. 2nd Edition. Sydney: McGraw‐Hill / H. Kilham [et al.] // - 2009. – Handbook, 2nd Edition 2nd Edition Р. 79.
43. Spinal cord pathology. In: Lin VW editor(s). Spinal Cord Medicine: Principles and Practice. 2nd Edition / R.C. Kim // J. New York: Demos Medical Publishing. – 2010. ‒ P.22-34.
44. The influence of complications on rehabilitation of spinal cord injuries: economical minus effects and physical disadvantages caused by urinary tract infection and decubitus ulcer / T. Kitagawa [et al.]// Journal of Nippon Medical School [Nihon Ika Daigahu Zasshi]. ‒ 2002. ‒ Vol.69, №3. ‒ P.268-77.
45. Inhibition of expression of a staphylococcal superantigen-like protein by a soluble factor from Lactobacillus reuteri/ J. Laughton [et al.]// J. Microbiology. ‒ 2006. – Vol.152, №4. ‒ P.1155‐67.
46. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults.[Erratum appears in Clin Infect Dis. 2005 May 15;40(10):1556]/ L.E. Nicolle [et al.]// J. Clinical Infectious Diseases. ‒ 2005. – Vol.40, №5. ‒ P.643-54.
47. A bacterial interference strategy for prevention of UTI in persons practicing intermittent catheterization /Prasad A. [et al.]// J. Spinal Cord. ‒ 2009. – Vol.47, №7. ‒ P.565‐9.
48. Probiotic lactobacillus dose required to restore and maintain a normal vaginal flora/ G. Reid [et al.]//J. FEMS Immunology & Medical Microbiology. ‒ 2001. – Vol.32, №1. ‒ P.37-41.
49. Probiotics to prevent urinary tract infections: the rationale and evidence/ G. Reid [et al.]// World Journal of Urology. - 2006. – Vol.24, №1.-P.28‐32.
50. Mortality associated with nosocomial bacteremia due to methicillin‐resistant Staphylococcus aureus / J. Romero-Vivas [et al.]// J. Clinical Infectious Diseases. ‒1995. ‒ Vol.21, №6. ‒ P.1417-23.
51. Probiotics, prebiotics, and synbiotics approaching a definition/ J. Schrezenmeir [et al.]// American Journal of Clinical Nutrition. ‒ 2001. – Vol.73, №2. ‒ P.361-4.
52. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Stamm WE. Protocol for diagnosis of urinary tract infection: reconsidering the criterion for significant bacteriuria/H.J. Schünemann [et al.]// J. Urology. ‒ 1988. ‒ Vol.32, №2. ‒ P.6-12.
53. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors)/ H.J. Schünemann [et al.]// J. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 – 2011. – Р. 49.
54. Probiotics for preventing urinary tract infections in adults and children/ E.M. Schwenger [et al.]// J. Cochrane Database of Systematic Reviews. ‒ 2015.
55. The standardization of terminology in neurogenic lower urinary tract dysfunction: with suggestions for diagnostic procedures/ M. Stohrer [et al.]// International Continence Society Standardization Committee. Neurourology & Urodynamics. ‒ 1999. ‒ Vol.18, №2. ‒ P.139-58.
56. Methicillin resistant staphylococcus aureus in patients with spinal cord injury/ J.D. Thom [et al.]//Journal of Spinal Cord Medicine. ‒ 1999. ‒ Vol.22, №2. ‒ P.125- 31.
57. Interference in initial adhesion of uropathogenic bacteria and yeasts to silicone rubber by a Lactobacillus acidophilus biosurfactant / M.M. Velraeds [et al.]// Journal of Medical Microbiology. ‒ 1998. ‒ Vol.47, №12. ‒ P.1081-5.
58. Epidemiology and risk factors for urinary tract infection following spinal cord injury/ K.B. Waites [et al.]// J. Archives of Physical Medicine & Rehabilitation. ‒ 1993. ‒ Vol.74, №7. ‒ P.691-5.
59. Antimicrobial resistance in gram-negative bacteria isolated from the urinary tract in community-residing persons with spinal cord injury/K.B. Waites [et al.]// J. Archives of Physical Medicine & Rehabilitation. – 2000. ‒ Vol.8, №6. ‒ P.764-9.
